Bryostatin 1 Inhibits Phorbol Ester-Induced Apoptosis in Prostate Cancer Cells by Differentially Modulating Protein Kinase C (PKC) δ Translocation and Preventing PKCδ-Mediated Release of Tumor Necrosis Factor-α

Vivian A. von Burstin, Liqing Xiao, and Marcelo G. Kazanietz

Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Received March 15, 2010; accepted June 1, 2010

ABSTRACT

Bryostatin 1, a macrocyclic lactone that has been widely characterized as an ultrapotent protein kinase C (PKC) activator, displays marked pharmacological differences with the typical phorbol ester tumor promoters. Bryostatin 1 impairs phorbol 12-myristate 13-acetate (PMA)-induced tumor promotion in mice and is in clinical trials as an anticancer agent for a number of hematopoietic malignancies and solid tumors. In this study, we characterized the effect of bryostatin 1 on LNCaP prostate cancer cells, a cellular model in which PKC isoforms play important roles in the control of growth and survival. Although phorbol esters promote a strong apoptotic response in LNCaP cells via PKCδ-mediated release of TNFα, bryostatin 1 failed to trigger a death effect even at high concentrations, and it prevented PMA-induced apoptosis in these cells. Mechanistic analysis revealed that bryostatin 1 is unable to induce TNFα release, and it impairs the secretion of this cytokine from LNCaP cells in response to PMA. Unlike PMA, bryostatin 1 failed to promote the translocation of PKCδ to the plasma membrane. Moreover, bryostatin 1 prevented PMA-induced PKCδ peripheral translocation. Studies using a membrane-targeted PKCδ construct revealed that the peripheral localization of the kinase is a requisite for triggering apoptosis in LNCaP cells, arguing that mislocalization of PKCδ may explain the actions of bryostatin 1. The identification of an antiapoptotic effect of bryostatin 1 may have significant relevance in the context of its therapeutic efficacy.

Introduction

Activation of protein kinase C (PKC) isoforms leads to a plethora of cellular responses, including mitogenesis, cell growth arrest, survival, apoptosis, differentiation, and transformation. This family of serine-threonine kinases has been originally identified as the major cellular target for the phorbol esters and related tumor promoters. Biochemical and structural analysis established that two subgroups, namely the classical (cPKCs, βI, βII, and γ) and the novel (nPKCs δ, ε, η, and θ) PKCs, bind phorbol esters with nanomolar affinity and respond to the lipid second-messenger diacylglycerol (DAG), a product of membrane phospholipid hydrolysis. Phorbol esters and DAG bind to the C1 domains present in the N-terminal regulatory region of PKCs, an event that triggers the activation of these kinases (Griner and Kazanietz, 2007). Members of the PKC family have been extensively implicated in the control of the cell cycle, apoptotic cascades, and survival pathways. For example, PKCδ activation leads to cell growth arrest through multiple mechanisms, including up-regulation of the cell cycle inhibitor p21cip1, reduction in cyclin levels, and dephosphorylation of the retinoblastoma protein. PKCδ is required for the apoptotic cell death induced by phorbol esters and chemotherapeutic agents such as etoposide. On the other hand, PKCe generally activates survival and mitogenic pathways in normal and cancer cells (Reyland et al., 1999; Blass et al., 2002; Basu and Sivaprasad, 2007; Griner and Kazanietz, 2007).

Pharmacological manipulation of PKC isoforms gained importance not only for understanding the basic biological processes and players in DAG signaling but also because of its therapeutic relevance. In fact, phorbol esters, DAG analogs, and other PKC activators are in clinical trials for cancer
treatment (Barry and Kazanietz, 2001; Schaar et al., 2006). The bryostatins, natural products isolated from the marine organism Bugula neritina, are atypical PKC modulators. These compounds are ultrapotent activators of PKC isoforms in vitro that bind to C1 domains in cPKCs and nPKCs (Kazanietz et al., 1994). However, although bryostatins mimic several phorbol ester responses, they display unusual pharmacological properties because they fail to induce phorbol ester-like responses in many cellular models. More interestingly, bryostatins functionally antagonize phorbol ester responses that they themselves are unable to elicit, including tumor promotion (Hennings et al., 1987; Szallasi et al., 1994). Bryostatin 1, a prototype bryostatin analog, exhibits characteristic anticancer effects, because it inhibits tumor growth, invasion, and angiogenesis, and it is currently in phase I and II clinical trials against a number of cancers, both alone and in combination with other antineoplastic agents (Propper et al., 1998; Varterasian et al., 2000; Zonder et al., 2001; Clamp et al., 2003; Roberts et al., 2006).

Although phorbol esters exert major effects on cell survival and proliferation, a number of cell types undergo apoptotic cell death in response to phorbol ester treatment (Powell et al., 1996; Reyland et al., 2000; Gonzalez-Guerrero and Kazanietz, 2005). LNCaP prostate cancer cells emerged as one of the most extensively characterized models that undergo apoptosis in response to PKC activators. Our laboratory established that in LNCaP prostate cancer cells, phorbol 12-myristate 13-acetate (PMA) induces apoptosis primarily through the activation of PKCδ (Tanaka et al., 2003; Gonzalez-Guerrero and Kazanietz, 2005). A thorough analysis of the mechanisms underlying this response led to the identification of a PKCδ-mediated autocrine loop that involves the secretion of death factors, primarily TNFα. Impairing this autocrine loop essentially abolishes phorbol ester-induced apoptosis (Gonzalez-Guerrero and Kazanietz, 2005).

In the present studies, we established that the failure of bryostatin 1 to cause LNCaP cell death is due to its inability to translocate PKCδ to the plasma membrane and promote TNFα release. Moreover, bryostatin 1 functionally antagonizes peripheral PKCδ translocation and TNFα release from prostate cancer cells in response to phorbol ester stimulation.

Materials and Methods

Materials. PMA was purchased from LC Laboratories (Woburn, MA). Bryostatin 1 was purchased from EMD Biosciences (Gibbstown, NJ). 4',6-Diamidino-2-phenylindole (DAPI) was obtained from Roche Diagnostics (Indianapolis, IN). Recombinant human TNFα was purchased from PeproTech Inc. (Rocky Hill, NJ).

Cell Culture. LNCaP cells (American Type Culture Collection, Manassas, VA) were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum from HyClone Laboratories (Logan, UT), penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37°C in a humidified 5% CO2 atmosphere. Cells were used from passages 2 to 8.

Western Blot Analysis. Cells were harvested in lysis buffer containing 50 mM Tris-HCl, pH 6.8, 10% glycerol, and 2% β-mercaptoethanol. Equal amounts of protein (20 μg protein/lane) were subjected to SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Millipore Corporation, Billerica, MA). After blocking with 5% milk, membranes were incubated with primary antibodies against PKCα, myc (Millipore Corporation), PKCδ (Cell Signaling Technology Inc., Danvers, MA), PKCζ (Santa Cruz Biotechnology Inc., Santa Cruz, CA), vinculin, or β-actin (Sigma-Aldrich, St. Louis, MO). After extensive washing, membranes were incubated for 1 h with either anti-mouse or anti-rabbit secondary antibodies conjugated to horseradish peroxidase (1:5000; Bio-Rad Laboratories, Hercules, CA). Bands were visualized by enhanced chemiluminescence.

RNA Interference. Double-stranded siRNAs for PKC isoforms were purchased from Dharmacon RNA Technologies (Lafayette, CO). The following target sequences were used: PKCα-1, CCAGAAGGCUCCACACUCUC; PKCα-2, GAACAAACAAGGAAUGACUUC; PKCδ1, CCAUGAGUUUAUCGCCAC; PKCδ2, CAGCAGCAAGCGUGGGGAAA; PKCζ1, GUGGAGAGGAGCUAUGUUU; and PKCζ2, GACGUGGACUCAGCAUGUA. As controls, we used either Silencer Negative Control siRNA1 or Silencer Negative Control siRNA2 (Ambion, Austin, TX). siRNAs (120 pmol) were transfected into LNCaP cells (2 × 10⁶) using the Amaxa nucleofector (Amaxa Biosystems, Gaithersburg, MD), and experiments were carried out 48 h after transfection (Gonzalez-Guerrero and Kazanietz, 2005).

Treatment of LNCaP Cells and Generation of Conditioned Medium. LNCaP cells (~70% confluent) were treated for 1 h with PMA or bryostatin 1 alone or in combination, or vehicle. After 24 h, cells were collected for the determination of apoptosis. Alternatively, conditioned medium (CM) was collected, filtered through a 0.45 μm syringe filter (Fisher Scientific, Waltham, MA), added to naive LNCaP cells (~70% confluence), and apoptosis was determined 24 h later.

Generation of Myristoylated PKCδ Constructs. PKCδ containing a C-terminal myc-tag was polymerase chain reaction-amplified from pShooterPKCδ (generous gift from Dr. Chaya Brodie, Henry Ford Hospital, Detroit, MI) and flanked with 5’-XbaI and 3’-EcoR1 restriction sites. The polymerase chain reaction product was cloned into XbaI and EcoRI sites in pCMV6myr (kindly provided by Dr. Alex Toker, Harvard Medical School, Boston, MA). In the resulting construct (PKCδmyr), PKCδ is N-terminally fused to a myristoylation signal sequence and contains a C-terminal myc-tag.

Transfections. Expression vectors encoding PKCδmyco, PKCδmyr, or empty vector (pcDNA3.1) were transfected (2 μg) into LNCaP cells using the Amaxa Nucleofector according to the manufacturer’s instructions. Cells were assayed for apoptosis 24 h after transfection.

Apoptosis Assay. Apoptosis was determined as described previously (Tanaka et al., 2003; Xiao et al., 2008).

Immunofluorescence and Confocal Microscopy. For localization studies of GFP-fused PKCs, LNCaP cells were transfected with 2 μg of pEGFP-N1-PKCa, pEGFP-N1-PKCa, or pEGFP-N1-PKζ using the Amaxa Nucleofector and plated on coverslides in 12-well plates. After 48 h, cells were stimulated with PMA and/or bryostatin 1, washed with PBS, and fixed with precooled methanol (~ −20°C). Samples were stained with DAPI (1 μg/ml) for 10 min at 4°C, mounted on a glass slide, and visualized with a Zeiss LSM 510 META NLO laser scanning confocal microscope (Carl Zeiss Inc., Thornwood, NJ). In a different set of experiments, LNCaP cells transfected with plasmids encoding myc-tagged PKCs were fixed as described above and incubated with a rabbit polyclonal anti-myc antibody for 1 h at room temperature in 5% bovine serum albumin (1:500), followed by incubation with a secondary Alexa Fluor 488-coupled antibody (1:2000; Invitrogen, Carlsbad, CA) for 1 h at room temperature. Slides were washed, counterstained with DAPI, and visualized by confocal microscopy.

Enzyme-Linked Immunosorbent Assay. TNFα levels in CM were determined with a Human ELISA Development Kit from PeproTech Inc. in 96-well plates. Measurements were done in triplicate.

Statistical Analysis. Analysis of variance was performed using GraphPad Prism software built-in analysis tools (GraphPad Software, Inc., San Diego, CA). The confidence interval was set to 95%. A p < 0.05 was considered statistically significant.

Results

Bryostatin 1 Fails to Induce Cell Death and Inhibits PMA-Induced Apoptosis in LNCaP Cells. Most PKC ago-
nists, including phorbol esters, DAGs, and ingenol-3-angelate (PEP005), bind to the C1 domains in cPKCs and nPKCs leading to kinase activation in vitro. In androgen-dependent prostate cancer cells, these PKC activators induce a strong apoptotic response (Garcia-Bermejo et al., 2002; Ogbourne et al., 2004; Gonzalez-Guerrico and Kazanietz, 2005; Xiao et al., 2009). However, previous studies showed that long-term treatment (24–72 h) of LNCaP prostate cancer cells with bryostatin 1, another C1 domain ligand for PKCs, does not affect LNCaP cell viability. Such long-term treatment causes a marked down-regulation of PKC isozymes, primarily PKCα (Gschwend et al., 2000). We were interested in the effects of short-term treatment with bryostatin 1 on LNCaP cells, an effect that should be independent of PKC down-regulation.

Indeed, short treatment (1 h) of LNCaP cells with bryostatin 1 (0.1–100 nM) did not appreciably change the expression of PKCα, PKCδ, or PKCe, the 3 phorbol ester- and bryostatin-responsive PKCs expressed in these cells (Fig. 1A). As we reported previously (Tanaka et al., 2005), a 1-h treatment with PMA caused a marked apoptotic response in LNCaP cells. On the other hand, bryostatin 1 failed to cause apoptosis at all concentrations tested (0.1–100 nM) under similar experimental conditions. Moreover, coincubation of bryostatin 1 with PMA inhibited the apoptotic effect of the phorbol ester in a dose-dependent manner (Fig. 1B). In agreement with a previous study (Gschwend et al., 2000), a 24-h treatment with bryostatin 1 also failed to promote LNCaP apoptotic cell death. Representative micrographs of LNCaP cultures and nuclear DAPI stainings in response to the different treatments are shown in Fig. 1C. These results suggest that bryostatin 1 acts as a functional antagonist of PMA-induced apoptosis in LNCaP prostate cancer cells.

**Bryostatin 1 Prevents PMA-Stimulated Release of TNFα from LNCaP Cells.** Previous studies from our laboratory established that PMA promotes the release of death factors from LNCaP cells, primarily TNFα. RNA interference (RNAi) depletion or inhibition of TACE (the enzyme responsible for TNFα shedding), neutralization of TNFα in the CM, or blockade/depletion of TNFα receptors markedly reduces PMA-induced apoptosis in LNCaP cells, arguing for a critical involvement of this autocrine loop in the death effect of the phorbol ester (Gonzalez-Guerrico and Kazanietz, 2005). To determine whether alterations in autocrine mechanisms are responsible for the inhibition of PMA-induced apoptosis by bryostatin 1, we compared the apoptotic activity of CM collected from cells treated with vehicle (CM-vehicle), bryostatin 1 (CM-Bryo1), PMA (CM-PMA), or bryostatin 1 and PMA (CM-Bryo1/PMA). When added to naive LNCaP cells (recipient cells), CM-PMA induced a prominent apoptotic response, as we reported previously (Gonzalez-Guerrico and Kazanietz, 2005). On the other hand, like CM-vehicle, CM-Bryo1 failed to induce apoptosis. It is noteworthy that the apoptotic effect of CM-Bryo1/PMA was significantly lower than that of CM-PMA (Fig. 2A). These results suggest that bryostatin 1 not only fails to promote the release of death factors from LNCaP cells, it also prevents the secretion of apoptogenic factors that are otherwise released in response to phorbol ester stimulation.

Next, we examined the effect of bryostatin 1 on TNFα release from LNCaP cells. In our previous studies (Gonzalez-Guerrico and Kazanietz, 2005; Xiao et al., 2009) we established that PMA causes a marked release of this cytokine, as determined by ELISA, and that this effect was abolished by either TACE inhibition or TACE RNAi depletion. We have extensively ruled out that the effect was related to any carryover of C1 domain ligand (Gonzalez-Guerrico and Kazanietz, 2005). Using a similar approach, we found that unlike PMA, bryostatin 1 treatment failed to induce any measurable release of TNFα from LNCaP cells. The representative micrographs of LNCaP cell cultures (left) and apoptotic cells, as indicated with arrows (right), 24 h after treatment with PMA and/or bryostatin 1 (100 nM).

![Fig. 1. Short-term bryostatin 1 treatment prevents PMA-induced apoptosis in LNCaP cells.](https://example.com/fig1.png)
release of TNFα from LNCaP cells, and more importantly, it essentially blunted TNFα release by PMA (Fig. 2B).

To determine whether the reduced secretion of TNFα is a critical determinant for the impaired apoptotic response of PMA by bryostatin 1, we pursued a rescue approach adding exogenous TNFα to the CM. We reasoned that by supplementing this cytokine to CM-Bryo1/PMA to levels similar to those normally observed in CM-PMA, we would be able to restore the apoptotic response. A caveat in this same experiment is that the final concentration of TNFα was <20% than that added to the CM \( y = 180.2x + 2.4, R^2 = 0.9999; \) where \( y \) is TNFα in CM (in picograms per milliliter) and \( x \) is added TNFα (in nanograms per milliliter). Possible reasons for this reduced recovery may be decreased stability and/or misfolding of the synthetic TNFα. It is noteworthy that the addition of exogenous TNFα was able to rescue the proapoptotic effect of CM-Bryo1/PMA in a concentration-dependent manner (Fig. 2C). Based on the linear correlation established between the added and measured TNFα concentrations in the CM, we were able to estimate the actual TNFα concentrations in CM-Bryo1/PMA. Data clearly show that complete rescue could be achieved at concentrations of TNFα that were in a range similar to those present in the CM (compare with Fig. 2B).

**PKCδ Is a Key Regulator of PMA-Induced TNFα Release from LNCaP Cells.** A previous report showed that the ability of bryostatin 1 to impair PMA-induced apoptosis is related to the ability to down-regulate PKCα from LNCaP cells, although unlike our studies, that was a long-term (24–72 h) treatment (Gschwend et al., 2000). Because our previous studies assigned a key role for PKCδ in PMA-induced apoptosis (Tanaka et al., 2003), we decided to explore this issue in more detail by means of an RNAi approach. The three PMA-responsive PKCs expressed in LNCaP cells were individually knocked down using two different siRNA duplexes in each case, which minimized misinterpretation of results because of “off-target” effects of RNAi. We successfully achieved isozyme-specificity depletion for each PKC with either duplex relative to cells transfected with control siRNA (Fig. 3A). Our data revealed that the apoptotic effect of PMA was substantially reduced in PKCδ-knockdown LNCaP cells but not in cells in which either PKCα or PKCε was depleted (Fig. 3B). A slightly higher apoptotic effect of PMA was observed in PKCα-depleted LNCaP cells, consistent with its prosurvival effect in this model (McJilton et al., 2003; Meshki et al., 2010). Most importantly, only PKCδ depletion could significantly impair TNFα release by the phorbol ester, whereas depletion of either PKCα or PKCε failed to block secretion of the death factor (Fig. 3C). These data not only suggest that PKCδ is crucial for PMA-induced TNFα release in LNCaP cells, they also argue in favor of PKCδ as the main PKC implicated in the protection of PMA-induced apoptosis by bryostatin 1.

**Bryostatin 1 Selectively Inhibits the Translocation of PKCδ to the Plasma Membrane in LNCaP Cells.** At this point, we raised the question of whether bryostatin 1 could induce changes in the subcellular localization of PKCδ. It is well established that translocation of PKC isozymes is a hallmark of enzyme activation. We speculated that the failure of bryostatin 1 to induce apoptosis in LNCaP cells may relate to its failure to translocate PKCδ to the plasma membrane, which may ultimately lead to the inability to release TNFα. To this end, we assessed the translocation using GFP-fused PKCs. LNCaP cells were transfected with pEGFP-N1-PKCα, pEGFP-N1-PKCδ, or pEGFP N1-PKCε, and 48 h after transfection, cells were treated with PMA or bryostatin 1, alone or in combination. Localization of the GFP-fused PKCs was assessed by confocal microscopy. PMA redistributed PKCα and PKCδ to the plasma membrane, whereas PKCε is dually translocated to the plasma and nuclear membranes (Figs. 4, C, G, and K). Similar patterns of translocation for these PKCs have been reported in various cell types (Wang et al., 1999a, 2004; Garcia-Bermejo et al., 2002). Like PMA, bryostatin 1 caused significant translocation of PKCα and
PKCε to the cell periphery, although the effect was less pronounced for PKCα (Fig. 4, B and J). On the other hand, bryostatin 1 caused a pronounced translocation of PKCδ to the nuclear membrane, but remarkably, translocation to the plasma membrane could not be readily detected (Fig. 4F). PMA retained its ability to translocate PKCα and PKCε to the cell periphery when LNCaP cells were cotreated with bryostatin 1 (Fig. 4, D and L). In contrast, peripheral relocalization of PKCδ by PMA was significantly reduced in cells treated with bryostatin 1, whereas accumulation of PKCδ at the nuclear membrane remained essentially unaffected (Fig. 4H). Therefore, these findings demonstrate a different subcellular relocalization of PKCδ depending on the ligand. Most importantly, they reveal that bryostatin 1 has the ability to prevent the translocation of PKCδ to the plasma membrane without significantly altering the distribution of other PKCs.

It is therefore conceivable that translocation of PKCδ to the plasma membrane is a requisite for the induction of apoptosis in LNCaP cells by PKC activators.

**Translocation of PKCδ to the Plasma Membrane Is Essential for the Induction of Apoptosis in LNCaP Cells.** Localization of PKC isoforms is key for determining the nature of the cellular response to PKC activators. PKCs can differentially translocate to multiple compartments in a cell type-specific manner, leading ultimately to a differential access to substrates or accessory interacting proteins (Schechterman and Mohly-Rosen, 2002; Gomez et al., 2007). Our data point to plasma membrane redistribution of PKCδ as an essential step for PMA-induced apoptosis in LNCaP cells. To test this hypothesis, we generated a construct in which PKCδ was fused at the N terminus to a myristoylated (myr) tag that directs the kinase to the plasma membrane and at the C terminus to an myc-tag for detection. LNCaP cells were transfected with plasmids encoding either wild-type PKCδ, which localizes essentially in the cytoplasm (PKCδcyto) or the membrane-targeted PKCδ (PKCδmyr), and apoptosis was assessed 24 h later. Transfection efficiencies were ~15%, as determined with vectors encoding GFP (data not shown). Expression by Western blot is shown in Fig. 5A. Upon ectopic expression of PKCδcyto in LNCaP cells, we could not detect any measurable apoptotic response. In contrast, ectopic expression of PKCδmyr resulted in significant cell death (Fig. 5B). Similar effects were observed upon expression of a constitutively active PKCδmyr mutant (data not shown). To confirm the localization of PKCδmyr at the plasma membrane, confocal microscopy was performed. As shown in Fig. 5C, this modified the form of the kinase localized exclusively in the cell periphery, whereas PKCδcyto was found essentially in the cytoplasm of LNCaP cells. Thus, targeting PKCδ to the plasma membrane is sufficient to promote apoptosis in LNCaP cells. Taken together, our data strongly argue that the lack of an apoptotic response in...
response to bryostatin 1 and the abrogation of PMA-induced apoptosis by bryostatin 1 are due to the inability of PKCδ to translocate to the plasma membrane.

**Discussion**

Studies in animal models established that the marine-derived macrocyclic lactone bryostatin 1 displays pronounced antitumor activity. Moreover, remarkable antiproliferative and apoptotic activities for bryostatin 1 have been reported in numerous cancer cell lines (Stone et al., 1988; Wang et al., 1998, 1999b). Bryostatin 1 is in phase II clinical trials for the treatment of various solid cancers, such as melanoma, colorectal, ovarian and cervical cancers, and hematopoietic cancers (Propper et al., 1998; Varterasian et al., 2000; Zonder et al., 2001; Clamp et al., 2003; Roberts et al., 2006). The effectiveness of bryostatin 1 for the treatment of prostate cancer still remains to be determined. Our limited understanding on how bryostatin 1 modulates prostate cancer cellular fate and exerts actions in prostate models via its main targets, the PKC isozymes, has greatly limited the development of preclinical studies with this drug for prostate cancer.

Unlike phorbol esters and DAG analogs, the typical PKC activators, bryostatin 1 is unable to kill LNCaP prostate cancer cells. Moreover, bryostatin 1 treatment prevents PMA from inducing apoptosis in LNCaP cells. Our previous studies established that PKCδ is the main mediator of phorbol ester-induced apoptosis in LNCaP cells (Tanaka et al., 2003; Gonzalez-Guerrico and Kazanietz, 2005; Xiao et al., 2009). However, despite the ability of bryostatin 1 to strongly activate PKCδ in vitro (Kazanietz et al., 1994), this compound failed to translocate PKCδ to the plasma membrane in LNCaP cells, arguing that the cellular context is key for determining the outcome of the bryostatin 1 response. It is noteworthy that bryostatin 1 treatment was unable to stimulate TNFα release from LNCaP cells. PMA, on the other hand, depends on the autocrine secretion of this cytokine for killing prostate cancer cells (Gonzalez-Guerrico and Kazanietz, 2005). The impaired TNFα secretion by PMA when cells are simultaneously treated with bryostatin 1 seems to fully account for the functional antagonism. Indeed, adding back this cytokine at final concentrations similar to those normally observed in CM-PMA fully restores the apoptotic activity. It is interesting that bryostatin 1 is able to promote apoptosis and TNFα release from leukemia cells (Cartee et al., 2003; Wang et al., 2003), suggesting a strict cell-type dependence for the differential killing ability of this agent. TNFα release from prostate cancer cells by PMA is mediated by PKCδ (Gonzalez-Guerrico and Kazanietz, 2005). This paradigm has been validated recently in vascular smooth muscle cells (Reddy et al., 2009). Although the mechanistic basis of this process is not yet understood, PKC has been implicated in TACE activation and TNFα ectodomain shedding in several models (Shao et al., 2003; Wheeler et al., 2003). TACE may be a direct PKC substrate, a paradigm that would certainly require PKCδ relocalization to the plasma membrane. Indeed, several putative PKC phosphorylation sites could be predicted in TACE using the NetPhosK 1.0 Server with Evolutionary Stable Sites filtering (http://www.cbs.dtu.dk/services/NetPhosK/). Alternatively, TACE may be phosphorylated by PKC downstream effector kinases, as reported previously (Diaz-Rodriguez et al., 2002). In any given scenario, our data established that relocalization of PKCδ to the plasma membrane of LNCaP cells is required for promoting an apoptotic response. Remarkably, expression of a membrane (myr)-targeted PKCδ in LNCaP cells is sufficient to promote apoptosis. Moreover, limiting the access of PKCδ to the plasma membrane prevents the apoptotic effect of PMA.

The ability of bryostatin 1 to differentially translocate PKC isozymes is a well-documented phenomenon. Early studies using GFP-tagged PKCs revealed distinctive patterns of translocation for PKC isozymes in living cells in response to different PKC activators and other stimuli. In this regard, it is striking that ligands that are all capable of binding with high affinity to the C1 domains confer such distinct patterns of PKC relocalization, a paradox that is particularly observed for PKCδ (Wang et al., 1999a, 2000). The pattern of translocation of PKCδ in LNCaP cells resembles that observed originally in Chinese hamster ovary cells, in which bryostatin 1 translocates PKCδ predominantly to the nuclear membrane (Wang et al., 1999a). Our studies revealed that in LNCaP cells, bryostatin 1 prevents PKCδ translocation to the plasma membrane by PMA but still allows for nuclear membrane relocalization of PKCδ and without significantly affecting translocation of PKCe or PKCc to the plasma membrane. It is noteworthy that an early study showed that bryostatin 1 differentially protects PKCδ from down-regulation by PMA (Lorenzo et al., 1997), suggesting major differences in the regulation of each PKC isozyme by bryostatins. Our results strongly support the hypothesis that bryostatin 1 exerts its
antia apoptotic effects in LNCaP cells through a functional antagonism driven by mislocalization of PKCδ, ultimately restraining the access of this kinase to plasma membrane substrates. The basis for the differential subcellular translocation for PMA and bryostatin 1 remains to be determined. The complexities of the mechanisms governing the interactions between the C1 domain in PKCs, C1 domain ligands, and the lipid bilayers are indeed poorly understood. Studies by the Blumberg laboratory established that a key determinant for conferring ligand selectivity for PKC translocation is lipophilicity (Wang et al., 2000). It is tempting to speculate that PMA and bryostatin 1 exert their differential relocalization may have limited effectiveness in combination therapies with bryostatin 1 is involved in synergistic interactions with paclitaxel in human prostate cancer cells. 


Address correspondence to: Dr. Marcelo G. Kazanietz, University of Pennsylvania School of Medicine, 1256 Biomedical Research Building II/III, 421 Curie Boulevard, Philadelphia, PA 19104-6160. E-mail: marcelog@upenn.edu